Editas Medicine earnings were -$237.1M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest EDIT earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$45.4M, down 26.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, EDIT reported annual earnings of -$237.1M, with 54.7% growth. The next EDIT earnings date is May 6, 2025.
What were Editas Medicine's earnings last quarter?
On EDIT's earnings call on Invalid Date, Editas Medicine (NASDAQ: EDIT) reported Q4 2024 earnings per share (EPS) of -$0.55, up 161.9% year over year. Total EDIT earnings for the quarter were -$45.40 million. In the same quarter last year, Editas Medicine's earnings per share (EPS) was -$0.21.
The next EDIT earnings call is Invalid Date. Add EDIT to your watchlist to be reminded of Editas Medicine's next earnings date.
Is Editas Medicine profitable or losing money?
As of the last Editas Medicine earnings report, Editas Medicine is currently losing money. Editas Medicine's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$237.09 million, a 54.74% increase year over year.
What was EDIT's earnings growth in the past year?
As of Editas Medicine's earnings date in Invalid Date, Editas Medicine's earnings has grown year over year. EDIT earnings in the past year totalled -$237.09 million.
What are Editas Medicine's earnings expectations?
The current EPS estimate for Editas Medicine's earnings report in Invalid Date is -$0.66.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.